Anti-Osteoprotegerin / TNFRSF11B

0.5mg/ml if reconstituted with 0.2ml sterile DI water. Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), also known as OPG, is a protein that in humans is encoded by the TNFRSF11B gene. OPG is a cytokine receptor, and a member of the tumor necrosis factor (TNF) receptor superfamily. By analysis of radiation hybrids, TNFRSF11B gene was mapped to chromosome 8q24. OPG is a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL). By binding RANKL, OPG inhibits nuclear kappa B (NF-?B) which is a central and rapid acting transcription factor for immune-related genes, and a key regulator of inflammation, innate immunity, and cell survival and differentiation. OPG binding to RANKL on osteoblast/stromal cells, blocks the RANKL-RANK ligand interaction between osteoblast/stromal cells and ostepclast precursors. Protein function: Acts as a decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis. [The UniProt Consortium]